Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis

NCT ID: NCT00049751

Last Updated: 2006-08-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

3000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate safety by collecting serious adverse events in subjects with moderately to severely active rheumatoid arthritis who are unable to obtain etanercept and who have failed one or more prior disease-modifying antirheumatic drugs (DMARDs).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adalimumab

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects must meet ACR criteria for diagnosis of RA for at least 3 months, must meet ACR Functional Class I, II or III (1992 criteria) and must have a confirmed diagnosis of active moderate to severe rheumatoid arthritis as defined by 6 or more swollen joints and 9 or more tender joints;
* must also have DAS of 3.2 or greater at study entry,
* normal laboratory parameters and ESR \>20,
* satisfactory response or intolerance to one or more prior DMARDs and
* be willing and able to give informed consent.

Exclusion:

* Previous treatment with total lymphoid irradiation or anti-CD4 or CAMPATH 1H monoclonal antibodies resulting in persistent CD4 lymphopenia,
* history of acute inflammatory joint disease other than RA,
* prior treatment with cyclophosphamide or chlorambucil,
* prior treatment with intravenous immunoglobulin within 70 days,
* history of malignant lymphoma,
* history of uncontrolled diabetes,
* unstable ischemic heart disease,
* active inflammatory bowel disease,
* active peptic ulcer disease or stroke,
* positive HIV status,
* positive serology for Hepatitis B or C,
* no previous history of tuberculosis or listeria infection,
* no previous history of cancer other than successfully treated skin cancer;
* women can not be pregnant or be breastfeeding
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

William M. Edwards, M.D.

Role: PRINCIPAL_INVESTIGATOR

Low Country Research Center, North Charelston SC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Thomas McGee, MD

Mobile, Alabama, United States

Site Status

Desert Valley Medical

Apple Valley, California, United States

Site Status

Kenneth Hsu, MD, Inc.

Bakersfield, California, United States

Site Status

Rheumatology Clinic

Los Angeles, California, United States

Site Status

Michael Harrington, MD

Napa, California, United States

Site Status

Midori Jane Nishio, MD

Walnut Creek, California, United States

Site Status

Naveen Raja, MD

Whittier, California, United States

Site Status

Mountain Rheumatology

Denver, Colorado, United States

Site Status

Division of Rheumatic Diseases/University of CT Health Center

Farmington, Connecticut, United States

Site Status

New Haven Medical Group, PC

New Haven, Connecticut, United States

Site Status

Norman Gaylis, MD

Aventura, Florida, United States

Site Status

Mike Schweitz, MD

West Palm Beach, Florida, United States

Site Status

Maurice McCarthy, MD

Winter Haven, Florida, United States

Site Status

Intermountain Orthopedics

Boise, Idaho, United States

Site Status

Institute of Arthritis Research

Idaho Falls, Idaho, United States

Site Status

Loyola University Medical Center

Maywood, Illinois, United States

Site Status

West Suburban Health Care

Oak Park, Illinois, United States

Site Status

OSF Medical Group -Rheumatology

Peoria, Illinois, United States

Site Status

Rockford Clinic, Clinical Research Department

Rockton, Illinois, United States

Site Status

Pain Therapy Center

Schaumburg, Illinois, United States

Site Status

Baton Rouge Clinic

Baton Rouge, Louisiana, United States

Site Status

Thomas Pressly, MD

Shreveport, Louisiana, United States

Site Status

Rheumatology Associates

Portland, Maine, United States

Site Status

Northampton Internal Medicine Association

Northampton, Massachusetts, United States

Site Status

Fallon Clinic Research

West Boylston, Massachusetts, United States

Site Status

John Howland, MD

Bay City, Michigan, United States

Site Status

Freeman Health Systems

Joplin, Missouri, United States

Site Status

Peggy Schlesinger, MD

Missoula, Montana, United States

Site Status

NJ Associates in Medicine

Fair Lawn, New Jersey, United States

Site Status

Internal Medicine and Rheumatic Diseases

Millburn, New Jersey, United States

Site Status

Placido Morano, MD

Brooklyn, New York, United States

Site Status

NYU Hospital for Joint Disease

New York, New York, United States

Site Status

Alan Kaell, MD

Port Jefferson Station, New York, United States

Site Status

Carolina Bone and Joint, PA

Monroe, North Carolina, United States

Site Status

Gordon Senter, MD Rheumatology, PA

Salisbury, North Carolina, United States

Site Status

MedCenter One Health Systems

Bismarck, North Dakota, United States

Site Status

University Hospital of Cleveland

Beachwood, Ohio, United States

Site Status

Arthritis Clinic

Canton, Ohio, United States

Site Status

STAT Research, Inc.

Dayton, Ohio, United States

Site Status

Arthritis and Osteoporosis Clinic, LLC

Bend, Oregon, United States

Site Status

Jel M. Depper, MD

Bend, Oregon, United States

Site Status

Sanford and Roumm Rheumatology

Camp Hill, Pennsylvania, United States

Site Status

Frederick Murphy, MD

Duncansville, Pennsylvania, United States

Site Status

Rheumatology Associates

Norristown, Pennsylvania, United States

Site Status

Rheumatology Associates, Ltd.

Sellersville, Pennsylvania, United States

Site Status

Low Country Research Center

North Charleston, South Carolina, United States

Site Status

Medical Specialists of Nashville

Nashville, Tennessee, United States

Site Status

Arthritis and Osteoporosis Clinical Research Center of Central Texas

Waco, Texas, United States

Site Status

Center of Arthritis and Rheumatic Disease, PC

Chesapeake, Virginia, United States

Site Status

Margaret Gradzka, MD

Fairfax, Virginia, United States

Site Status

Metropolitan Clinical Research

Falls Church, Virginia, United States

Site Status

Northern Virginia Center for Arthritis

Reston, Virginia, United States

Site Status

Lewis-Gale Clinic

Salem, Virginia, United States

Site Status

ROAD Clinic

Lakewood, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414-417. doi: 10.1136/annrheumdis-2016-209322. Epub 2016 Jun 23.

Reference Type DERIVED
PMID: 27338778 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

M02-498

Identifier Type: -

Identifier Source: org_study_id